MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases

BACKGROUND: Tamoxifen has anti-oestrogenic and anti-tumour activity in the breast, but is oestrogenic and carcinogenic in the endometrium. It can induce experimental tumours by both hormonal and DNA-damaging mechanisms, but its carcinogenic mode of action in human endometrium remains unclear. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, E, Gajjar, K B, Patel, I I, Taylor, S, Martin-Hirsch, P L, Stringfellow, H F, Martin, F L, Phillips, D H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056065/
https://www.ncbi.nlm.nih.gov/pubmed/24853176
http://dx.doi.org/10.1038/bjc.2014.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056065/
https://www.ncbi.nlm.nih.gov/pubmed/24853176
http://dx.doi.org/10.1038/bjc.2014.263

Ejemplares similares